The latest price of nivolumab in 2024

Nivolumab (Nivolumab) is an immune checkpoint inhibitor and a new type of immunotherapy drug. It treats cancer by regulating the immune system and is mainly used in the treatment of a variety of malignant tumors, including but not limited to advanced non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, etc.

Nivolumab is currently on the market in China and has been included in medical insurance. Patients can buy it domestically at a price of about four to five thousand yuan. For specific prices, please consult the local hospital pharmacy. The main ones abroad are Turkish original drugs, which cost around more than 2,000 yuan, and have the same ingredients and efficacy as the original drugs on the domestic market.

The main mechanism of action of nivolumab is to activate and enhance the patient's own immune system by blocking the PD-1 (programmed death -1) receptor on the immune checkpoint. PD-1 is an immune checkpoint protein. Under normal circumstances, it can inhibit the activity of T cells to prevent overactive autoimmune reactions. However, some tumor cells can use the PD-1 pathway to evade immune system attack, preventing cancer cells from being cleared by the immune system.

Nivolumab blocks the binding of PD-1 to its ligand PD-L1 (programmed death ligand -1), releasing the inhibition of T cells, allowing them to recognize, attack and eliminate cancer cells. Compared with traditional chemotherapy drugs, nivolumab is more specific and precise, which can improve the therapeutic effect and reduce adverse reactions. Therefore, it is considered an innovative and effective drug in the field of cancer treatment, bringing new treatment hope to many patients with advanced cancer.